Tower Research Capital LLC TRC Boosts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Tower Research Capital LLC TRC grew its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 39.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 3,163 shares of the specialty pharmaceutical company’s stock after buying an additional 889 shares during the period. Tower Research Capital LLC TRC’s holdings in Supernus Pharmaceuticals were worth $114,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in SUPN. Smartleaf Asset Management LLC lifted its holdings in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 870 shares during the period. Mark Sheptoff Financial Planning LLC purchased a new stake in Supernus Pharmaceuticals during the fourth quarter worth about $52,000. Headlands Technologies LLC grew its position in Supernus Pharmaceuticals by 203.0% during the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 1,015 shares during the period. Newbridge Financial Services Group Inc. purchased a new position in Supernus Pharmaceuticals in the fourth quarter valued at about $72,000. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter valued at approximately $92,000.

Insider Activity at Supernus Pharmaceuticals

In other news, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 9.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on SUPN shares. Cantor Fitzgerald restated a “neutral” rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com cut Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday.

Supernus Pharmaceuticals Price Performance

SUPN stock opened at $31.59 on Friday. The company’s 50 day simple moving average is $31.86 and its 200-day simple moving average is $34.90. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $40.28. The firm has a market capitalization of $1.77 billion, a PE ratio of 29.52 and a beta of 0.74.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.